Davenport & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

Davenport & Co’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,719	Closed	-$1.14M	–	1231
2025 Q2	$1.14M	Sell	4,719 -91,886	-95%	-$21.7M	0.01%	656
2025 Q1	$23.5M	Buy	96,605 +11,928	+14%	+$3.59M	0.14%	146
2024 Q4	$27.8M	Buy	84,677 +27,780	+49%	+$9.43M	0.16%	131
2024 Q3	$19M	Buy	56,897 +590	+1%	+$187K	0.11%	157
2024 Q2	$15.4M	Buy	56,307 +11,954	+27%	+$3.48M	0.09%	169
2024 Q1	$15.3M	Buy	+44,353	New	+$14.6M	0.09%	172
2022 Q1	–	Sell	-288	Closed	-$218K	–	1065
2021 Q4	$218K	Hold	288	–	–	﹤0.01%	1004
2021 Q3	$215K	Buy	+288	New	+$216K	﹤0.01%	956

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Davenport & Co's BIO Position: Q3 2025 in Review

Davenport & Co sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 4,719 shares — an estimated $1.14M sold.

Davenport & Co first reported a position in BIO in Q3 2021 and held it in 8 quarters. The position peaked at $27.8M in Q4 2024. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

Davenport & Co reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
Davenport & Co sold 4,719 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $1.14M.
Davenport & Co first reported a position in Bio-Rad Laboratories Class A in Q3 2021 and held it in 8 quarters.
Davenport & Co's Bio-Rad Laboratories Class A position peaked at $27.8M in Q4 2024.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Davenport & Co's 13F filing for Q3 2025, filed 15 Oct 2025.